Clinical Trial Update: Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia. [Phase 3]

View source ↗

Summary

Phase 3 trial of a fixed-dose combination of valsartan and rosuvastatin was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypertension

Drugs mentioned

• Valsartan + Rosuvastatin fixed-dose combination (valsartan and rosuvastatin)

Snippet

Sponsor: EMS | Conditions: Hypertension, Dyslipidemia | Phase 3 | Status: WITHDRAWN